- Home
- ALLO vs ADV Comparison
ALLO vs ADV Comparison
Compare ALLO & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- ADV
- Stock Information
- Founded
- ALLO 2017
- ADV 1987
- Country
- ALLO United States
- ADV United States
- Employees
- ALLO N/A
- ADV N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- ADV Business Services
- Sector
- ALLO Health Care
- ADV Consumer Discretionary
- Exchange
- ALLO Nasdaq
- ADV Nasdaq
- Market Cap
- ALLO 371.8M
- ADV 420.4M
- IPO Year
- ALLO 2018
- ADV N/A
- Fundamental
- Price
- ALLO $1.11
- ADV $1.17
- Analyst Decision
- ALLO Strong Buy
- ADV Strong Buy
- Analyst Count
- ALLO 10
- ADV 1
- Target Price
- ALLO $8.90
- ADV $2.50
- AVG Volume (30 Days)
- ALLO 4.1M
- ADV 485.7K
- Earning Date
- ALLO 05-13-2025
- ADV 05-12-2025
- Dividend Yield
- ALLO N/A
- ADV N/A
- EPS Growth
- ALLO N/A
- ADV N/A
- EPS
- ALLO N/A
- ADV N/A
- Revenue
- ALLO N/A
- ADV $3,526,704,000.00
- Revenue This Year
- ALLO N/A
- ADV N/A
- Revenue Next Year
- ALLO $9.07
- ADV N/A
- P/E Ratio
- ALLO N/A
- ADV N/A
- Revenue Growth
- ALLO N/A
- ADV N/A
- 52 Week Low
- ALLO $0.86
- ADV $1.04
- 52 Week High
- ALLO $3.78
- ADV $4.16
- Technical
- Relative Strength Index (RSI)
- ALLO 38.30
- ADV 41.73
- Support Level
- ALLO $1.07
- ADV $1.04
- Resistance Level
- ALLO $1.15
- ADV $1.30
- Average True Range (ATR)
- ALLO 0.14
- ADV 0.13
- MACD
- ALLO -0.01
- ADV 0.00
- Stochastic Oscillator
- ALLO 27.17
- ADV 25.44
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.